Needham & Company LLC Reiterates “Hold” Rating for Envista (NYSE:NVST)

Envista (NYSE:NVST)‘s stock had its “hold” rating restated by Needham & Company LLC in a report issued on Thursday,Benzinga reports.

A number of other brokerages also recently commented on NVST. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Jefferies Financial Group lifted their price target on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Wells Fargo & Company raised their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price on the stock. Finally, Morgan Stanley raised their price target on shares of Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.21.

Envista Price Performance

Envista stock opened at $18.28 on Thursday. The company has a fifty day simple moving average of $20.27 and a 200-day simple moving average of $19.69. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of -2.82, a PEG ratio of 1.27 and a beta of 1.33. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. Envista has a 52-week low of $15.15 and a 52-week high of $23.00.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, equities analysts anticipate that Envista will post 1 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

A number of institutional investors have recently modified their holdings of NVST. Ariel Investments LLC grew its position in Envista by 6.2% in the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock valued at $232,630,000 after acquiring an additional 699,625 shares in the last quarter. Nuance Investments LLC boosted its stake in shares of Envista by 4.4% in the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares during the period. Franklin Resources Inc. grew its holdings in shares of Envista by 72.6% in the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after purchasing an additional 2,882,844 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after buying an additional 1,089,923 shares during the period. Finally, Gates Capital Management Inc. lifted its holdings in Envista by 15.1% during the 4th quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock worth $90,550,000 after buying an additional 615,577 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.